A drug called cucurbitacin B (CuB) was found to directly target IGF2BP1 and block its recognition of m6A, resulting in the induction of apoptosis of cancer cells in vivo, the activation of immune cells into the TME and the reduction of PD-L1 expression in HCC, demonstrating substantial anti-HCC effects and improving the TME (173). Here, IGF2BP1 is linked to cancer.